2seventy bio (TSVT) Stock Forecast, Price Target & Predictions
TSVT Stock Forecast
2seventy bio stock forecast is as follows: an average price target of $2.00 (represents a -36.31% downside from TSVT’s last price of $3.14) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TSVT Price Target
The average price target for 2seventy bio (TSVT) is $2.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -36.31% downside from TSVT's last price of $3.14.
TSVT Analyst Ratings
According to 7 Wall Street analysts, 2seventy bio's rating consensus is 'Buy'. The analyst rating breakdown for TSVT stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
2seventy bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 06, 2024 | Salveen Richter | Goldman Sachs | $2.00 | $4.56 | -56.14% | -36.31% |
| May 02, 2022 | Goldman Sachs | $26.00 | $13.46 | 93.16% | 728.03% |
The latest 2seventy bio stock forecast, released on Jun 06, 2024 by Salveen Richter from Goldman Sachs, set a price target of $2.00, which represents a -56.14% decrease from the stock price at the time of the forecast ($4.56), and a -36.31% decrease from TSVT last price ($3.14).
2seventy bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $3.14 | $3.14 | $3.14 |
| Upside/Downside | -100.00% | -100.00% | -36.31% |
In the current month, the average price target of 2seventy bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 2seventy bio's last price of $3.14. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 12, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Jun 06, 2024 | Goldman Sachs | Buy | Sell | Downgrade |
| Apr 07, 2024 | Citigroup | Buy | Buy | Hold |
| Jan 31, 2024 | Leerink Partners | Outperform | Upgrade | |
| Sep 13, 2023 | Guggenheim | Neutral | Downgrade | |
| Mar 17, 2023 | Wedbush | Outperform | Outperform | Hold |
| Jan 10, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| May 02, 2022 | Goldman Sachs | Buy | Initialise | |
| Apr 26, 2022 | Zacks Investment Research | Buy | Upgrade |
2seventy bio's last stock rating was published by Goldman Sachs on Nov 12, 2024. The company gave TSVT a "Sell" rating, the same as its previous rate.
2seventy bio Financial Forecast
2seventy bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $12.03M | - | $41.62M | $56.18M | $13.41M | $13.48M | $8.43M | $16.03K | $19.26M |
| Avg Forecast | $16.40M | $15.36M | $12.95M | $14.99M | $14.70M | $16.18M | $11.08M | $14.92M | $14.71M | $31.18M | $36.84M | $21.25M | $15.27M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| High Forecast | $17.82M | $16.69M | $14.07M | $16.29M | $16.66M | $17.58M | $11.08M | $14.92M | $23.72M | $33.88M | $40.03M | $23.09M | $16.60M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| Low Forecast | $14.54M | $13.61M | $11.48M | $13.29M | $11.80M | $14.34M | $11.08M | $14.92M | $7.72M | $27.64M | $32.66M | $18.84M | $13.54M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.39% | - | 1.96% | 3.68% | 1.08% | 0.82% | 0.43% | 0.00% | 2.26% |
2seventy bio's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.71M, with a low forecast of $7.72M, and a high forecast of $23.72M. TSVT's average Quarter revenue forecast represents a 22.20% increase compared to the company's last Quarter revenue of $12.03M (Sep 23).
2seventy bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-33.76M | - | $-49.31M | $-24.79M | $-65.89M | $-73.50M | $-86.96M | $11.62M | $-55.33M |
| Avg Forecast | $-14.86M | $-13.91M | $-11.73M | $-13.58M | $-13.32M | $-14.66M | $-10.04M | $-13.52M | $-13.32M | $-28.24M | $-33.38M | $-19.25M | $-13.84M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| High Forecast | $-13.17M | $-12.33M | $-10.40M | $-12.04M | $-10.69M | $-12.99M | $-10.04M | $-13.52M | $-6.99M | $-25.04M | $-29.59M | $-17.07M | $-12.27M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| Low Forecast | $-16.14M | $-15.12M | $-12.75M | $-14.76M | $-15.09M | $-15.92M | $-10.04M | $-13.52M | $-21.49M | $-30.69M | $-36.27M | $-20.92M | $-15.03M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.20% | - | 2.56% | 1.79% | 5.98% | 4.99% | 4.94% | -1.01% | 7.29% |
3 analysts predict TSVT's average Quarter EBITDA for Mar 22 to be $-17.59M, with a high of $-17.59M and a low of $-17.59M. This is -251.32% lower than 2seventy bio's previous annual EBITDA (Dec 21) of $11.62M.
2seventy bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-71.64M | - | $-42.48M | $-23.14M | $-67.44M | $-77.42M | $-80.93M | $-60.97K | $-60.00M |
| Avg Forecast | $522.63K | $-3.48M | $-6.27M | $-6.97M | $-8.84M | $-10.09M | $-34.80M | $-38.99M | $-54.10M | $-60.05M | $-53.91M | $-65.63M | $-81.31M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| High Forecast | $581.46K | $-2.97M | $-5.35M | $-5.94M | $-7.51M | $-8.61M | $-29.66M | $-33.24M | $-41.24M | $-51.19M | $-45.95M | $-55.95M | $-69.31M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| Low Forecast | $445.53K | $-3.88M | $-6.98M | $-7.75M | $-10.17M | $-11.23M | $-38.71M | $-43.38M | $-60.75M | $-66.81M | $-59.97M | $-73.01M | $-90.46M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.19% | - | 0.65% | 0.28% | 0.69% | 0.65% | 0.70% | 0.00% | 0.44% |
2seventy bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
2seventy bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.00M | - | $20.72M | $18.70M | $19.61M | $17.28M | $23.86M | $24.48K | $23.00M |
| Avg Forecast | $17.99M | $16.84M | $14.20M | $16.45M | $16.13M | $17.74M | $12.15M | $16.36M | $16.13M | $34.20M | $40.41M | $23.31M | $16.75M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| High Forecast | $19.55M | $18.30M | $15.43M | $17.87M | $18.27M | $19.28M | $12.15M | $16.36M | $26.02M | $37.16M | $43.91M | $25.33M | $18.20M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| Low Forecast | $15.95M | $14.93M | $12.59M | $14.58M | $12.94M | $15.73M | $12.15M | $16.36M | $8.47M | $30.32M | $35.83M | $20.66M | $14.85M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.38% | - | 0.89% | 1.12% | 1.45% | 0.95% | 1.10% | 0.00% | 2.46% |
2seventy bio's average Quarter SG&A projection for Dec 23 is $16.13M, based on 5 Wall Street analysts, with a range of $8.47M to $26.02M. The forecast indicates a 24.04% rise compared to TSVT last annual SG&A of $13.00M (Sep 23).
2seventy bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.40 | - | $-0.98 | $-649.41 | $-1.75 | $-2.02 | $-3.03 | $-0.00 | $-2.58 |
| Avg Forecast | $0.01 | $-0.07 | $-0.12 | $-0.13 | $-0.17 | $-0.19 | $-0.67 | $-0.75 | $-1.04 | $-1.15 | $-1.03 | $-1.26 | $-1.56 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| High Forecast | $0.01 | $-0.06 | $-0.10 | $-0.11 | $-0.14 | $-0.16 | $-0.57 | $-0.64 | $-0.79 | $-0.98 | $-0.88 | $-1.07 | $-1.33 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| Low Forecast | $0.01 | $-0.07 | $-0.13 | $-0.15 | $-0.19 | $-0.21 | $-0.74 | $-0.83 | $-1.16 | $-1.28 | $-1.15 | $-1.40 | $-1.73 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.22% | - | 0.78% | 417.44% | 0.99% | 0.94% | 1.44% | 0.00% | 1.03% |
According to undefined Wall Street analysts, 2seventy bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSVT previous annual EPS of $NaN (undefined).
2seventy bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| PHAT | Phathom Pharmaceuticals | $8.37 | $20.00 | 138.95% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.13 | $7.00 | 123.64% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| IOVA | Iovance Biotherapeutics | $7.81 | $12.40 | 58.77% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
| MRSN | Mersana Therapeutics | $2.03 | $3.00 | 47.78% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| TSVT | 2seventy bio | $3.21 | $2.00 | -37.69% | Buy |